内科理论与实践

内科理论与实践 >

2022 , Vol. 17 >Issue 01: 24 - 28

DOI: https://doi.org/10.16138/j.1673-6087.2022.01.005

专家论坛

原发性硬化性胆管炎的诊断与鉴别诊断

展开
  • 首都医科大学附属北京地坛医院肝病中心,北京 100015

收稿日期: 2022-01-21

  网络出版日期: 2022-07-25

基金资助

北京市属医院科研培育计划项目(PX 2022071)

收起

本文引用格式

杨松, 李玥 . 原发性硬化性胆管炎的诊断与鉴别诊断[J]. 内科理论与实践, 2022 , 17(01) : 24 -28 . DOI: 10.16138/j.1673-6087.2022.01.005

参考文献

[1] 中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 中华内科杂志, 2021, 60(12): 1050-1074.
[2] Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis—a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323.
[3] Mehta TI, Weissman S, Fung BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis[J]. Liver Int, 2021, 41(10): 2418-2426.
[4] Trivedi PJ, Bowlus CL, Yimam KK, et al. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2021.[Epub ahead of print].
[5] Mertz A, Nguyen NA, Katsanos KH, et al. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence[J]. Ann Gastroenterol, 2019, 32(2): 124-133.
[6] Lundberg Båve AA, Bergquist A, Bottai M, et al. Increased risk of cancer in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(5): 1174-1182.
[7] Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach[J]. Hepatol Int, 2021, 15(1): 6-20.
[8] Ponsioen CY, Assis DN, Boberg KM, et al. Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group Consensus Process[J]. Gastroenterology, 2021, 161(6): 1764-1775.
[9] Moiseev S, Cohen Tervaert JW, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis[J]. Autoimmun Rev, 2020, 19(9): 102618.
[10] Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis?[J]. Am J Gastroenterol, 2003, 98(5): 1155-1158.
[11] Keihanian T, Barakat MT, Tejaswi S, et al. Role of endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholestatic liver diseases[J]. Clin Liver Dis, 2022, 26(1): 51-67.
[12] Lüth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome[J]. J Clin Gastroenterol, 2009, 43(1): 75-80.
[13] Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline[J]. Endoscopy, 2017, 49(6): 588-608.
[14] Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J]. Gut, 2019, 68(8): 1356-1378.
[15] Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for primary sclerosing cholangitis 2017[J]. J Gastroenterol, 2018, 53(9): 1006-1034.
[16] de Vries EM, Verheij J, Hubscher SG, et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis[J]. J Hepatol, 2015, 63(5): 1212-1219.
[17] European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004.
[18] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华内科杂志, 2021, 60(12): 1038-1049.
[19] Tanaka A, Tazuma S, Okazaki K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 920-926.
[20] 张文, 董凌莉, 朱剑, 等. IgG 4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206.
[21] Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2019, 26(1): 9-42.
[22] Nakazawa T, Kamisawa T, Okazaki K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020[J]. J Hepatobiliary Pancreat Sci, 2021, 28(3): 235-242.
[23] Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-related disease[J]. Arthritis Rheumatol, 2020, 72(1): 7-19.
[24] Manganis CD, Chapman RW, Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels[J]. World J Gastroenterol, 2020, 26(23): 3126-3144.
[25] Lapidot Y, Amir A, Ben-Simon S, et al. Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(1): 191-201.
[26] Liu Q, Li B, Li Y, et al. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut, 2021.[Epub ahead of print].
[27] Moon SH, Kim MH, Lee JK, et al. Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis[J]. J Gastroenterol, 2017, 52(4): 483-493.
[28] Navaneethan U, Njei B, Venkatesh PG, et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis[J]. Gastrointest Endosc, 2014, 79(6): 943-950.
[29] Navaneethan U, Njei B, Venkatesh PG, et al. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis[J]. Gastroenterol Rep (Oxf), 2015, 3(3): 209-215.
[30] Weilert F, Bhat YM, Binmoeller KF, et al. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study[J]. Gastrointest Endosc, 2014, 80(1): 97-104.
[31] Scheid JF, Rosenbaum MW, Przybyszewski EM, et al. Next-generation sequencing in the evaluation of biliary strictures in patients with primary sclerosing cholangitis[J]. Cancer Cytopathol, 2021.[Epub ahead of print].
[32] Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review[J]. World J Gastroenterol, 2020, 26(3): 353-365.
[33] 郑卫萍. 危重患者继发性硬化性胆管炎的临床表现、胆管造影特征、自然病程及转归[J]. 实用器官移植电子杂志, 2016, 4(4): 247.
[34] Martins P, Verdelho Machado M. Secondary sclerosing cholangitis in critically ill patients[J]. GE Port J Gastroenterol, 2020, 27(2): 103-114.
[35] Klindt C, Jensen BE, Brandenburger T, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: a case report and review of the literature[J]. Clin Case Rep, 2021, 9(5): e04068.
[36] Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-covid-19 cholangiopathy: a new indication for liver transplantation[J]. Transplant Proc, 2021, 53(4): 1132-1137.
Options
文章导航

/

〈 〉